SELLAS Life Sciences Group Inc (SLS)
1.46
-0.01
(-0.68%)
USD |
NASDAQ |
May 17, 16:00
1.465
0.00 (0.00%)
After-Hours: 20:00
SELLAS Life Sciences Group Research and Development Expense (Annual): 24.01M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 24.01M |
| December 31, 2022 | 20.27M |
| December 31, 2021 | 15.67M |
| December 31, 2020 | 9.282M |
| December 31, 2019 | 7.285M |
| December 31, 2018 | 8.767M |
| December 31, 2017 | 6.067M |
| December 31, 2016 | 11.40M |
| December 31, 2015 | 23.61M |
| Date | Value |
|---|---|
| December 31, 2014 | 27.67M |
| December 31, 2013 | 20.42M |
| December 31, 2012 | 14.61M |
| December 31, 2011 | 3.851M |
| December 31, 2010 | 7.873M |
| December 31, 2009 | 8.892M |
| December 31, 2008 | 7.054M |
| December 31, 2007 | 6.747M |
| December 31, 2006 | 1.298M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
7.285M
Minimum
2019
24.01M
Maximum
2023
15.30M
Average
15.67M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Geron Corp | 125.05M |
| Immuneering Corp | 41.62M |
| Protagonist Therapeutics Inc | 120.16M |
| Akebia Therapeutics Inc | 63.08M |
| Moderna Inc | 4.845B |